Independent monitoring committee recommends halting REGN-COV2 trial

By The Science Advisory Board staff writers

November 2, 2020 -- The independent data monitoring committee of the REGN-COV2 antibody cocktail treatment trials for COVID-19 has recommended holding enrollment in hospitalized patients with high oxygen requirements and continuing enrollment in patients with low or no oxygen requirements.

The decision is based on a potential safety signal and an unfavorable risk/benefit profile at this time. The committee recommended further collection and data analysis of patients already enrolled. Lastly, the committee recommended continuing the outpatient trial without modification.

Regeneron Pharmaceuticals, the firm spearheading the trial, remains blinded to the data and is implementing the committee's recommendations. The firm is also informing the U.S. Food and Drug Administration (FDA), which is currently evaluating REGN-COV2 for a potential emergency use authorization (EUA) in mild-to-moderate outpatients at high risk for poor outcomes. Regeneron is also sharing the recommendation with the independent committee monitoring the Recovery trial in the U.K.

Regeneron's antibody cocktail improves COVID-19 patients
An investigational antibody cocktail by Regeneron Pharmaceuticals reduced the viral loads and improved the systems of nonhospitalized COVID-19 patients,...
Regeneron begins phase III trial of COVID-19 treatment in U.K.
Regeneron Pharmaceuticals and the University of Oxford have commenced a phase III clinical trial of potential treatments for COVID-19.
Regeneron, Roche increase supply of COVID-19 antibody cocktail
Regeneron Pharmaceuticals and Roche are joining forces to develop, manufacture, and distribute Regn-COV2, Regeneron's investigational antiviral antibody...
BARDA awards supply contract to Regeneron for COVID-19 cocktail
Regeneron Pharmaceuticals was awarded a $450 million contract to manufacture and supply its REGN-COV2 antibody cocktail that is currently in phase...
Regeneron begins COVID-19 antibody treatment phase III trial
Regeneron Pharmaceuticals has begun adaptive late-stage phase III clinical trials evaluating its antibody cocktail, REGN-COV2, for the treatment and prevention...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter